Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
500.00    0.00 (0.00%)
Bid:
499.80
Ask:
500.50
Spread: 0.70 (0.14%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Interim Management Statement

27 Feb 2013 07:00

RNS Number : 7388Y
Chemring Group PLC
27 February 2013
 



FOR IMMEDIATE RELEASE 27 FEBRUARY 2013

CHEMRING GROUP PLC

INTERIM MANAGEMENT STATEMENT

 

Chemring Group PLC ("Chemring" or "the Group") today issues its Interim Management Statement covering the period from 1 November 2012 to date, as required by Rule 4.3 of the Disclosure and Transparency Rules of the UK Listing Authority.

Current trading

Revenue from continuing operations during the first three month period was £136.1 million, compared with £132.4 million in the prior year. Improved trading performances in Pyrotechnics and Counter-IED were offset by weaker performances in Countermeasures and Munitions. Despite the general decline in current NATO defence spending, the Group's order book is currently £756.7 million, marginally lower than the £760.9 million order book at 31 October 2012. A weak order intake in Munitions was compensated by a stronger order intake in Counter-IED, where significant orders were awarded in the period, including a contract for Joint Services Lightweight Standoff Chemical Agent Detectors (US$28.5 million) with the US Army and a contract for the provision of Husky Mounted Detection System ('HMDS') Ground Penetrating Radar (US$32 million) with the US Army. 51.6% of the order book at the end of January 2013 was for delivery in the current financial year.

Counter-IED

Revenue from our Counter-IED business in the quarter was 33% higher than for the same period last year, when there was a pause in demand for HMDS from the US Department of Defense. The solid order intake in the period included the award to NIITEK of a contract for HMDS systems, together with spares and training, for the Spanish Army.

Countermeasures

Revenue at our Countermeasures business was 30% below the same period last year. This was primarily as a result of the lower opening order book and production delays at our US Countermeasures businesses, which are expected to be recovered during the course of the year.

Pyrotechnics and Munitions

Revenue in our Pyrotechnics business increased by 110% compared with the same period last year, whilst revenue at our Munitions business was 22% lower than the same period last year, reflecting the weighting of our production capacity towards smoke and illumination rounds for Middle East customers, rather than artillery ammunition. Order intake at our Munitions business continues to be impacted by delays in the placing of major contracts and by the granting of export licences.  

Current financial position

The Group's net debt at the end of January 2013 was £285.9 million (31 October 2012: £244.8 million, 31 January 2012: £316.9 million). The Group continues to closely manage cash and working capital balances.

Outlook

As outlined at the Group's preliminary results release on 24 January 2013, although budget uncertainties continue to impact wider market confidence across the Group's US, UK and European defence markets, Chemring remains focused on driving improvements in its operational performance and restructuring its businesses in order to provide the Group with greater resilience.

An update on progress made against the key priorities for 2013, as outlined at the Group's preliminary results release, will be given alongside Chemring's interim results in June 2013.

-ENDS-

 

For further information:

Mark Papworth

Chief Executive, Chemring Group PLC

01489 881880

Steve Bowers

Finance Director, Chemring Group PLC

01489 881880

Rupert Pittman

Group Director of Communications and Investor Relations,

Chemring Group PLC

01489 881880

Andrew Jacques

James White

 

MHP Communications

0203 128 8100

 

Cautionary statement

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

 

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

 

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

 

Notes to Editors

• Chemring is a manufacturing business with facilities in eight countries, selling high technology electronics and energetic products to over sixty countries worldwide.

• The Company has a diverse portfolio of products protecting military people and platforms against a constantly changing threat.

• Operating in niche markets with short product development timescales, Chemring has the agility to rapidly react to urgent customer needs.

• Strong R&D investment for new products and improvements in technology continually allows Chemring to expand its addressable markets.

www.chemring.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBCGDDSSDBGXL
Date   Source Headline
1st May 201910:07 amRNSTotal Voting Rights
10th Apr 20192:12 pmRNSDirector/PDMR Shareholding
8th Apr 20197:00 amRNSDisposal of Chemring Military Products, Inc.
2nd Apr 20195:44 pmRNSHolding(s) in Company
2nd Apr 201910:39 amRNSDirector/PDMR Shareholding
1st Apr 201910:29 amRNSTotal Voting Rights
25th Mar 20195:09 pmRNSDoc re. Ordinary & Special Resolutions
25th Mar 20193:40 pmRNSHolding(s) in Company
25th Mar 20193:36 pmRNSHolding(s) in Company
25th Mar 20198:51 amRNSDirector/PDMR Shareholding
25th Mar 20198:47 amRNSDirector/PDMR Shareholding
25th Mar 20198:47 amRNSDirector/PDMR Shareholding
21st Mar 20192:43 pmRNSResult of AGM
21st Mar 20197:00 amRNSAGM Trading Update
20th Mar 20194:03 pmRNSHolding(s) in Company
19th Mar 20197:11 amRNSDirector Declaration
1st Mar 201911:40 amRNSTotal Voting Rights
21st Feb 201910:27 amRNSDirector/PDMR Shareholding
20th Feb 20191:30 pmRNSNotice of Annual General Meeting
1st Feb 20191:55 pmRNSTotal Voting Rights
18th Jan 201910:17 amRNSDirector/PDMR Shareholding
17th Jan 20197:00 amRNSRESULTS FOR THE YEAR ENDED 31 OCTOBER 2018
7th Jan 20198:51 amRNSDirector Declaration
2nd Jan 20199:49 amRNSTotal Voting Rights
19th Dec 201811:40 amRNSBlock listing Interim Review
3rd Dec 20189:58 amRNSTotal Voting Rights
19th Nov 201811:31 amRNSDirectorate Change
19th Nov 201811:17 amRNSDirectorate Change
15th Nov 20187:00 amRNSPost year-end statement
16th Oct 20182:56 pmRNSHolding(s) in Company
2nd Oct 201810:21 amRNSTotal Voting Rights
5th Sep 20187:00 amRNSNGCD NOTIFICATION
4th Sep 20187:00 amRNSTrading Update
3rd Sep 20182:38 pmRNSTotal Voting Rights
16th Aug 20187:00 amRNSHMDS Contract award
15th Aug 201812:20 pmRNSHolding(s) in Company
13th Aug 20187:00 amRNSINCIDENT AT CHEMRING COUNTERMEASURES
8th Aug 20187:12 amRNSDirectorate Change
6th Aug 20182:16 pmRNSHolding(s) in Company
1st Aug 20189:32 amRNSTotal Voting Rights
30th Jul 20181:24 pmRNSDirector/PDMR Shareholding
2nd Jul 201810:44 amRNSTotal Voting Rights
2nd Jul 20187:00 amRNSCONTRACT AWARDS
26th Jun 20183:54 pmRNSDirector/PDMR Shareholding
22nd Jun 20182:40 pmRNSBlock listing Interim Review
22nd Jun 20182:39 pmRNSBlock listing Interim Review
21st Jun 20187:00 amRNSINTERIM RESULTS
8th Jun 20181:37 pmRNSAdditional Listing
4th Jun 20187:00 amRNSTotal Voting Rights
24th May 20187:00 amRNSCONTRACT AWARDS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.